{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3","upperLimit":"24","value":"8"}]}],"title":"2 Years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.8","upperLimit":"20","value":"4"}]}],"title":"1 Year"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Specifically, the 2-year cumulative risk of biopsy-proven recurrence anywhere in the larynx or neck following SABR. Recurrence in this context includes biopsy-proven cancer anywhere in the supraglottic, glottic, or subglottic larynx, as well as any malignant lymph node in the cervical or supraclavicular lymph nodes.","dispersionType":"90% Confidence Interval","groups":[{"description":"All patients on the clinical trial.","id":"OG000","title":"All Patients"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years","title":"Percentage of Participants With Locoregional Failure Following SABR With Death as a Competing Risk","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}